

examination, and differing societal contexts. Furthermore, few studies account for current health or health selection effects. Health-related predictors of childlessness may mediate the relationship between childlessness and late life wellbeing and/or influence wellbeing directly.

Methods This study utilises data from wave two of the Survey of Health, Ageing and Retirement in Europe (SHARE) and SHARELIFE (retrospective life history data) from 11 countries, spanning Northern, Western, Southern and Eastern Europe. The sample is restricted to those aged 55–75 years (N= 21,295). Two measures of wellbeing are employed: the EURO-D depressive mood scale and the CASP-12 quality of life scale. Standard demographic and socio-economic variables (age, gender education, employment, financial circumstance, marital status, and ethnicity) are utilised in addition to self-reported current and childhood health. Region-specific Ordinary Least Squares (OLS) regression analysis is performed to determine the independent effect of childlessness on each wellbeing measure, controlling for demographic, socio-economic and health variables. Interactions between childlessness and childhood health indicate the role of health selection in this relationship. Interactions between childlessness and marital status are also examined.

Results Childlessness significantly increases depressive mood in Northern Europe only. However, this effect is contingent on marital status; widowhood and never being married in particular. Relative to being currently married, never being married and widowhood also have a consistent main effect, reducing quality of life and increasing depressive mood. Across all regions there is no evidence to support the hypothesis that health selection mediates the relationship between childlessness and later life wellbeing.

Conclusion Marital status consistently mediates the relationship between childlessness and wellbeing and therefore should be the context through which the relationship between lifetime childlessness and wellbeing is considered.

OP19 SOCIAL NETWORKS AND DEPRESSIVE SYMPTOMS IN RUSSIA, POLAND AND THE CZECH REPUBLIC: EVIDENCE FROM THE HAPIEE STUDY

doi:10.1136/jech-2012-201753.019

¹M Franchi, ¹H Pikhart, ¹M Bobak, ^{1,2}R Kubinova, ^{1,2}S Maluyutina, ¹S Croezen. ¹Department of Epidemiology and Public Health, University College London, London, UK; ²Siberian Branch of the Russian Academy of Medical Sciences, Novosibirsk, Russia

Background In countries of Central and Eastern Europe, prevalence rates of depressive symptoms are as high as 20% in men and 40% in women. Inclusion in social networks has been found to be a strong predictor of depressive symptoms in other countries, but little research on this association has been carried out in Central and Eastern Europe. This study aims to examine this association in the adult urban population in Russia, Poland and the Czech Republic.

Methods Cross-sectional analysis was performed on baseline data (2002–2005) from the Health Alcohol and Psychosocial factors In Eastern Europe (HAPIEE) study, involving men and women aged 45–69 from the adult urban population of the three countries of interest (Total N=25,674). Depressive symptoms were measured by the Centre for Epidemiological Studies Depression (CESD-20) scale. Inclusion in social networks was measured in terms of trust in informal or formal networks, and frequency of contacts with friends and distant relatives.

Results In Russia and the Czech Republic, odds of depressive symptoms were higher for men (Russia, OR 3.94, 95%CI 2.37–6.54; Czech Republic OR 2.04, 95%CI 1.18–3.52) and women (Russia, OR 2.19, 95%CI 1.47–2.99; Czech Republic OR 1.87, 95%CI 1.10–3.16) who had nobody to rely upon, compared with those who relied on friends or family. The pattern of association between frequency of contact with distant relatives or friends and depressive symptoms varied according to gender and country of origin of participants. Not having relatives outside the household was

predictive of depressive symptoms among Polish men (OR 1.54, 95% C.I. 1.10–2.15) and women (OR 2.01, 95% C.I. 1.36–2.97); and not having any friends was associated with higher odds of depressive symptoms among Russian women (OR 1.54, 95% C.I. 1.09–2.19), and Polish men (OR 1.60, 95% C.I. 1.15–2.22).

Conclusion The results presented here suggest that exclusion from social networks is a strong predictor of depressive symptoms and that there is a country specific pattern of variation in how frequency of contact with social networks affects the risk of depressive symptoms. We argue that this variation could be due to differences in economic development and social capital of Russia, Poland and the Czech Republic.

OP20 A COMPARATIVE ANALYSIS OF DEPLOYMENT ASSOCIATED MENTAL HEALTH ISSUES IN UNITED STATES AND UNITED KINGDOM ARMED FORCES

doi:10.1136/jech-2012-201753.020

¹J Sundin, ¹NT Fear, ¹N Greenberg, ²L Riviere, ²R Herrell, ³A Adler, ²C Hoge, ²P Bliese, ⁴S Wessely. ¹ACDMH, King's College London, London, UK; ²Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research, Silver Spring, USA; ³US Army Medical Research Unit-Europe, Walter Reed Army Institute of Research, Germany; ⁴King's Centre for Military Health Research, King's College London, London, UK

Background There are several differences in health outcomes between UK and US military personnel who have deployed to the recent conflicts in Iraq or Afghanistan. Rates of survey-based post-traumatic stress disorder (PTSD) tend to be higher in US personnel, whilst self-reported rates of alcohol use tend to be higher in UK personnel. To explore potential reasons why mental health prevalence rates differ in the two countries a comparative analysis of UK and US Armed Forces combined data was carried out.

Methods Two samples of UK (n=313) and US (n=1560) regular enlisted Army male personnel who were deployed to Iraq in 2007 were combined. Primary outcomes included PTSD, alcohol use, anger and physical symptoms. The samples were compared on a list of 11 combat experiences, socio-demographics and military characteristics.

Results There were several differences between the UK and US samples: the UK sample was younger, more likely to hold a degree and a rank of officer, had served for a longer time, more likely to be married or in a long term relationship, and more likely to rate their marriage as good. The US sample reported more combat experiences. The samples did not differ on physical symptoms, but the US sample was more likely to report PTSD, adjusted odds ratio (AOR) 1.75 (95% Confidence Interval 1.01 – 3.03) and less likely to report alcohol misuse, AOR 0.27 (95% CI 0.20 – 0.37) compared to the UK sample.

Conclusion US military personnel deployed to Iraq were more likely to report PTSD whilst UK personnel are more likely to report alcohol misuse. Whilst, there were several differences between the US and UK samples in terms of socio-demographics and combat experiences, these did not explain the difference in health outcomes.

Understanding the differences, as well as the similarities, between the UK and US Armed Forces is important, as it can influence the way military personnel are managed in both nations. It can also influence the way military personnel who have developed mental health problems as a result of their service are treated.

HSR: Economics and Cost-Effectiveness Analysis

OP21 AN ECONOMIC EVALUATION OF NON-COMMUNICABLE DISEASES IN BRAZIL

doi:10.1136/jech-2012-201753.021

¹K Rtveladze, ¹T Marsh, ¹M Brown, ¹L Webber, ¹F Kilpi, ²F McPherson, ³D Levy, ⁴W Conde, ⁴C Monteiro. ¹Micro Health Simulations, UK; ²University of Oxford, UK; ³University of Georgetown, USA; ⁴University of Sao Paulo, Brazil

Background Non-communicable diseases are increasingly recognised as the major health issue facing many governments. Brazil has observed a rapid change in the weight profiles of its population, with the prevalence of obesity and overweight increasing partly as a result of the well documented effect of the nutrition transition. Obesity-related diseases are placing a substantial health and economic burden on the country. While the problem has been recognized, the implications of current trends on future overweight and obesity rates, BMI-related disease and costs associated with that disease burden have not been considered.

Methods A previously developed micro-simulation model was used to project through the year 2050 the extent of obesity, BMI related diseases, and associated health care costs in Brazil. A Monte-Carlo simulation method has been utilized to simulated BMI related diseases. In total, thirteen conditions were modelled: coronary heart disease, stroke, hypertension, diabetes, knee osteoarthritis, and eight cancers (breast, kidney, colorectal, oesophageal, endometrial, gallbladder, liver and pancreas). The authors also projected a possible decrease in the BMI and its impact on health and health care costs.

Results In 2010, nearly 45% of the Brazilian male population were overweight or obese (BMI $\geq 25\text{kg/m}^2$), but by 2050 we project rates as high as 95%. A slightly less pessimistic picture is observed among females: 42% in 2010 increasing to 52% in 2050. The disease incidence figures increase considerably due to obesity patterns. However, BMI reduction across the population will alter these disease projections. Nearly three million diabetes cases and USD 388 million in health care expenditure can be avoided with a five percent reduction in BMI alone by 2050.

Conclusion Obesity rates are rapidly increasing in Brazil creating a high burden of diseases and associated health care costs. However, even a one and percent reduction in prevalence rates will substantially reduce the disease and cost burden. Though some steps have been taken for tackling the obesity problem, Brazil still needs a strong, comprehensive policy involving multiple agencies and institutions with strong leadership.

OP22 PROJECTIONS OF HEALTHCARE COSTS IN THE LAST YEAR OF LIFE FOR OLDER CANCER PATIENTS IN EUROPEAN UNION MEMBER STATES (2008-2030)

doi:10.1136/jech-2012-201753.022

H Petkova, D Dawoud, P McCrone, IJ Higginson. ¹Department of Palliative Care, Policy and Rehabilitation, King's College London, London, UK; ²Department of Palliative Care, Policy and Rehabilitation, King's College London, London, UK; ³Health Service and Population Research Department, King's College London, Institute of Psychiatry, London, UK; ⁴Department of Palliative Care, Policy and Rehabilitation, King's College London, London, UK

Background Despite advances, cancer remains a major cause of pain, suffering and death. The highest incidence and mortality occurs in older people (≥ 65), and given demographic change the numbers are expected to rise in the coming years. This has financial consequences and key implications for service planning. We estimated the current and future cost of providing care for older cancer patients in the last year of life (LYOL) in the 27 European Union (EU) member-states between 2008 and 2030.

Methods Our cost projection models combined: a) WHO-GLOBOCAN mortality data; b) an average UK-based estimate of the cost of care per cancer patient in the LYOL; c) country-specific adjustment factor; d) annual cost inflation correction range 5%–15%: 5% (conservative scenario), 10% (realistic scenario), 15% (highest expected increase scenario), and e) an adjustment for ageing to reflect the increasing life expectancy (LE) and the related morbidity expansion.

Results The total EU cost of care for older cancer patients in the LYOL is expected to increase by 48% (2008–2030) reflecting

mortality rates only (baseline model). Assuming 5% cost rise per year (model 1), we projected more than a two-fold increase in the total EU cost by 2030 at an average annual rate of 9.6%. Model 2 involved 10% inflation and no ageing-adjustment, predicting a 3.7 times cost rise during the next two decades. This equated an annual average increase at 16.9%. We predicted a slightly higher cost rise when we allowed for ageing in addition to the 10% annual inflation (model 3) at approximately 17% increase year on year. This represents \$81 billion absolute increase during the projected period or \$3.6 average annual increase for Europe as a whole. The highest cost increase is expected in model 4 (15% inflation with ageing-adjustment). Costs are predicted to rise more than five times between 2008 and 2030, marking a 24.3% average annual increase. There is a marked cost variation across Europe.

Conclusion Costs of care for older cancer patients in the LYOL are projected to rise substantially in the foreseeable future. Our models outline cost variation between 2.2% and 24.3%, with the most realistic increase expected at 17% annually. This has key implications for short and medium-term service planning of how to provide care in the LYOL for the rising number of older citizens dying from cancer, taking into account the current economic climate in Europe.

OP23 DEVELOPING A SINGLE, EVIDENCE-BASED APPROACH TOWARDS DISINVESTMENT: IS A NICE WAY THE RIGHT WAY?

doi:10.1136/jech-2012-201753.023

H Flynn, CA Gericke. PenCLAHRC, The Universities of Plymouth and Exeter, Plymouth, UK

Background With the NHS currently facing one of its toughest periods financially, most, if not all, PCTs in England have started to prioritise services and sought to identify those which are either ineffective or of low clinical value for disinvestment. Yet the absence of a nationally accepted list of identified procedures has resulted in PCTs developing their own approaches, with many applying different priority thresholds to different procedures. This has created numerous “black lists” of interventions which will either not be funded or their commissioning severely curtailed. As these decisions are being based on the affordability of procedures rather than clinical efficacy, a post-code lottery in provision has ensued across the UK. Therefore to ensure equitable access to healthcare resources, an evidence based approach towards disinvestment is imperative.

Methods Working in collaboration with NICE R&D, the project used NICE's ‘do not do’ (DND) database to identify topics based on rigorous evidence for potential disinvestment. DNDs based upon those treatments with evidence suggesting they are ineffective or of low-clinical value were identified from the 850 + DND database. DNDs relating solely to clinical safety were excluded from the study. Procedures were further prioritised by 34 clinical experts in participating ‘pilot’ implementation sites in the SW Peninsula, who were asked to review populated lists of DNDs to ensure: clinical soundness; practicality of implementation; and any DND of potential high impact locally. Using HES data, volumes of DNDs still being performed in the NHS were also collated to give an estimate of overall usage and potential impact. Each DND identified was subjected to a cost analysis to provide an estimate of potential savings at both a local and national level.

Results 209 DND topics developed between 2007 and 2012 were identified for use in the study. Following local clinical prioritisation, cost analysis and exploration of HES data to give an estimate of usage, 30 procedures for a pilot disinvestment programme were identified solely from the NICE DND database.

Conclusion The study successfully developed a single, evidence-based approach towards disinvestment through the identification of ineffective and low clinical value treatments from the NICE DND database. Additional planned research which will implement the ‘pilot’ list across the SW Peninsula, will provide valuable information